SG160391A1 - Cladribine regimen for treating multiple sclerosis - Google Patents

Cladribine regimen for treating multiple sclerosis

Info

Publication number
SG160391A1
SG160391A1 SG201001736-6A SG2010017366A SG160391A1 SG 160391 A1 SG160391 A1 SG 160391A1 SG 2010017366 A SG2010017366 A SG 2010017366A SG 160391 A1 SG160391 A1 SG 160391A1
Authority
SG
Singapore
Prior art keywords
multiple sclerosis
treating multiple
cladribine
regimen
cladribine regimen
Prior art date
Application number
SG201001736-6A
Other languages
English (en)
Inventor
Luca Giampiero De
Arnaud Ythier
Alain Munafo
Maria Lopez-Bresnahan
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36227798&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG160391(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of SG160391A1 publication Critical patent/SG160391A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
SG201001736-6A 2004-12-22 2005-12-20 Cladribine regimen for treating multiple sclerosis SG160391A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63866904P 2004-12-22 2004-12-22
EP04106909 2004-12-22

Publications (1)

Publication Number Publication Date
SG160391A1 true SG160391A1 (en) 2010-04-29

Family

ID=36227798

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201001736-6A SG160391A1 (en) 2004-12-22 2005-12-20 Cladribine regimen for treating multiple sclerosis

Country Status (24)

Country Link
US (2) US7713947B2 (ja)
EP (6) EP4070800A1 (ja)
JP (7) JP5795456B2 (ja)
KR (1) KR20070091662A (ja)
AR (1) AR052830A1 (ja)
AU (2) AU2005318190B2 (ja)
BR (1) BRPI0517132B8 (ja)
CA (2) CA3087419C (ja)
CY (3) CY1112614T1 (ja)
DK (2) DK2805723T3 (ja)
EA (1) EA015799B1 (ja)
ES (1) ES2921858T3 (ja)
FR (1) FR18C1008I2 (ja)
HR (1) HRP20120228T1 (ja)
HU (2) HUE059133T2 (ja)
IL (2) IL183930A0 (ja)
LT (2) LT3332789T (ja)
LU (1) LUC00064I2 (ja)
MX (1) MX2007007610A (ja)
NO (1) NO20073813L (ja)
PL (3) PL1827461T3 (ja)
SG (1) SG160391A1 (ja)
SI (2) SI3332789T1 (ja)
WO (1) WO2006067141A1 (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007135172A2 (en) 2006-05-24 2007-11-29 Laboratoires Serono S.A. Cladribine regimen for treating multiple sclerosis
EP2343074A1 (en) 2009-12-23 2011-07-13 Merck Serono S.A. Use of purine analogues for treating airway diseases
WO2011117267A1 (en) 2010-03-24 2011-09-29 Merck Serono Sa Cladribine treatment of multiple sclerosis in patient groups defined by genotype
EP2428201A1 (en) 2010-09-08 2012-03-14 Merck Serono S.A. Oral administration of nucleoside monophosphates
WO2012097867A1 (en) 2011-01-18 2012-07-26 Synthon Bv Cladribine particles and pharmaceutical compositions comprising them
GB201401465D0 (en) 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease
GB2564717A (en) * 2017-07-21 2019-01-23 Chord Therapeutics S A R L Use of cladribine for treating autoimmune neuromuscular disease
JP2021504363A (ja) * 2017-11-24 2021-02-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 進行型多発性硬化症の処置における使用のためのクラドリビン処方計画
GB2601786A (en) * 2020-12-10 2022-06-15 Chord Therapeutics S A R L Use of cladribine for treating immune brain disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1269659A (en) 1984-08-06 1990-05-29 Brigham Young University Method for the production of 2'-deoxyadenosine compounds
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US4964848A (en) * 1988-06-27 1990-10-23 Bloom Philip M Treatment of multiple sclerosis with lymphocytapheresis and chemo-immunosuppression
US5208327A (en) 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
US5641757A (en) 1994-12-21 1997-06-24 Ortho Pharmaceutical Corporation Stable 2-chloro-2'-deoxyadenosine formulations
DK0801571T3 (da) 1994-12-22 2003-01-06 Ortho Pharma Corp Opløselige 2'-chlor-2'-deoxyadenosion-formuleringer
US6194395B1 (en) 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
WO2000064918A1 (en) 1999-04-28 2000-11-02 Sterrenbeld Biotechnologie North America, Inc. METHOD FOR THE PRODUCTION OF 2-CHLORO-2'-DEOXYADENOSINE (CLADRIBINE) AND ITS 3,5-DI-O-p-TOLUOYL DERIVATIVE
DE10237146A1 (de) * 2002-08-13 2004-03-04 Medac Gesellschaft für klinische Spezialpräparate mbH Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose
WO2004028462A2 (en) 2002-09-25 2004-04-08 Brigham Young University, Technology Transfer Office Method for the preparation of 2-halo-2'-deoxyadenosine compounds from 2'-deoxyguanosine
GB2394658A (en) * 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
AU2004216485B2 (en) * 2003-02-25 2009-06-11 Merck Serono Sa Combined use of ribavirin and interferon beta in demyelinating diseases
ES2584183T3 (es) 2003-03-28 2016-09-26 Ares Trading S.A. Formulaciones de cladribina para suministro mejorado oral y transmucosa
PL1608344T3 (pl) 2003-03-28 2011-01-31 Ares Trading Sa Doustne formulacje kladrybiny
WO2007135172A2 (en) * 2006-05-24 2007-11-29 Laboratoires Serono S.A. Cladribine regimen for treating multiple sclerosis

Also Published As

Publication number Publication date
US20100203017A1 (en) 2010-08-12
EP3332789A1 (en) 2018-06-13
CY2018006I1 (el) 2018-06-27
US8377903B2 (en) 2013-02-19
CY1112614T1 (el) 2016-02-10
AU2011200768A1 (en) 2011-03-17
SI2805723T1 (en) 2018-02-28
EA015799B1 (ru) 2011-12-30
LT3332789T (lt) 2022-07-25
HUE059133T2 (hu) 2022-10-28
BRPI0517132B8 (pt) 2021-05-25
SI3332789T1 (sl) 2022-08-31
EP2275110A3 (en) 2011-04-27
WO2006067141A1 (en) 2006-06-29
FR18C1008I1 (ja) 2018-03-30
JP5795456B2 (ja) 2015-10-14
FR18C1008I2 (fr) 2019-03-01
AU2011200768B2 (en) 2012-09-13
HUS1800009I1 (hu) 2018-05-02
LUC00064I1 (ja) 2018-02-14
EP2263678B1 (en) 2014-06-11
LTC2805723I2 (lt) 2022-04-25
AR052830A1 (es) 2007-04-04
PL3332789T3 (pl) 2022-08-22
BRPI0517132B1 (pt) 2020-02-18
LTPA2018503I1 (lt) 2018-03-12
EP4070800A1 (en) 2022-10-12
AU2005318190B2 (en) 2010-11-25
EP2805723B1 (en) 2018-01-17
JP2020193206A (ja) 2020-12-03
MX2007007610A (es) 2007-08-03
AU2005318190A1 (en) 2006-06-29
CY2018006I2 (el) 2018-06-27
CA2588966A1 (en) 2006-06-29
EP2275110B1 (en) 2013-07-10
EP3332789B1 (en) 2022-04-06
US20090081163A1 (en) 2009-03-26
CA3087419A1 (en) 2006-06-29
JP2013216664A (ja) 2013-10-24
CY1119790T1 (el) 2018-06-27
LUC00064I2 (ja) 2018-03-28
DK3332789T3 (da) 2022-07-11
PL2805723T3 (pl) 2018-04-30
JP6092945B2 (ja) 2017-03-08
EP2275110A2 (en) 2011-01-19
EP2805723A1 (en) 2014-11-26
BRPI0517132A (pt) 2008-09-30
JP2017101061A (ja) 2017-06-08
IL212421A (en) 2014-01-30
JP6430554B2 (ja) 2018-11-28
ES2921858T3 (es) 2022-09-01
NO20073813L (no) 2007-09-21
HRP20120228T1 (hr) 2012-04-30
KR20070091662A (ko) 2007-09-11
PL1827461T3 (pl) 2012-07-31
JP6290962B2 (ja) 2018-03-07
US7713947B2 (en) 2010-05-11
DK2805723T3 (da) 2018-01-29
EP1827461B1 (en) 2012-02-29
EA200701221A1 (ru) 2008-02-28
EP2263678A3 (en) 2011-04-27
IL183930A0 (en) 2007-10-31
EP2263678A2 (en) 2010-12-22
CA2588966C (en) 2020-07-21
JP5908863B2 (ja) 2016-04-26
IL212421A0 (en) 2011-06-30
JP2015180685A (ja) 2015-10-15
JP2008524313A (ja) 2008-07-10
EP1827461A1 (en) 2007-09-05
JP2018165271A (ja) 2018-10-25
CA3087419C (en) 2023-03-07
JP2016138128A (ja) 2016-08-04

Similar Documents

Publication Publication Date Title
SG160391A1 (en) Cladribine regimen for treating multiple sclerosis
TW200635923A (en) Tricyclic heterocycles, their manufacture and use as pharmaceutical agents
TW200619220A (en) New hydrates and polymorphs of 4-[[(7r)-8-cyclopentyl-7-ethyl-5, 6, 7, 8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-mithoxy-n-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
TW200508214A (en) Novel compounds
TW200722081A (en) New therapeutic combinations for the treatment or prevention of depression
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
TW200640908A (en) Chemical compounds
TW200634003A (en) Chemical compounds
TW200616974A (en) Chemical compounds
RS20090083A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta -mimetics
TW200630093A (en) Dose forms
IL228952A0 (en) Medicinal preparations containing ferric-citrate for reducing the level of phosphate in the serum, and their use in the preparation of medicines for the treatment or relief of calcium-related disorders
WO2003082853A8 (en) New compounds
MY148125A (en) Compounds
WO2007135172A3 (en) Cladribine regimen for treating multiple sclerosis
TW200639156A (en) New compounds
HRP20041092A2 (en) New pharmaceutical compositions containing filbanserin polymorph a
TW200634002A (en) Chemical compounds
UA104281C2 (ru) Противоопухолевые аналоги пептидов, способ их получения и фармацевтическая композиция на них основе
BRPI0618370A2 (pt) formulação aerossol de medicamento, uso do mesmo e kit de inalação
SI1827461T1 (sl) Kladribinski režim za zdravljenje multiple skleroze
TW200720239A (en) Styrylsulfonamides, their manufacture and use as pharmaceutical agents
MX2009005125A (es) Pirrolo[1,2-a]imidazoldiona efectiva en el tratamiento de neurotoxicidad periferica inducida por agentes quimioterapeuticos.
TW200626149A (en) Tricycles, their manufacture and use as pharmaceutical agents
MX2009003930A (es) Novedoso cristal de (s)-(+)-2-(2-clorofenil)-2-hidroxi-etil carbamato.